Gastric Balloons Market

Executive Summary

Gastric Balloons Market was valued at US $38.75 million in 2021 and is projected to grow at 13.96% CAGR over the forecast period to reach US $84.89 million by 2027. Gastric Balloons Market represented US $8.91 million opportunity over 2019-2021 and estimated to create US $46.14 million opportunity in 2027 over 2021.

Gastric Balloons from Consainsights analyses the Gastric Balloons Market in the Life Sciences industry over the forecast period to 2027.

Gastric Balloons research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Gastric Balloons segmentation includes Product Type, Filling Material, Insertion Method and Geography.

Based on the Product Type, the Gastric Balloons analysis covers Single Gastric Balloons, Dual Gastric Balloons, Triple Gastric Balloons.

In Product Type segment, Single Gastric Balloons segment has highest cagr growth of 12.32%.

Based on the Filling Material, the Gastric Balloons analysis covers Saline Filled Balloons, Gas Filled Balloons.

In Filling Material segment, Saline Filled Balloons segment has highest cagr growth of 12.32%.

Based on the Insertion Method, the Gastric Balloons analysis covers Endoscopic, Oral.

In Insertion Method segment, Endoscopic segment has highest cagr growth of 12.32%.

Based on the region, the Gastric Balloons analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Obalon Therapeutics, Inc., Allurion Technologies, Apollo Endosurgery, Inc., Districlass Medical SA, Helioscopie Medical Implants, Silimed, Inc. (Sientra), Medsil, ReShape Medical ( ReShape Lifesciences Inc.), Spatz Cosmeceutical Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, Single Gastric Balloons segment has the highest revenue of US $21.60 million and is expected to grow at CAGR of 12.32% by 2027 Single Gastric Balloons segment has highest cagr growth of 12.32%.

Single Gastric Balloons

Single Gastric Balloons segment was valued at US $16.63 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $47.32 million by 2027. Single Gastric Balloons segment represented US $4.97 million opportunity over 2019-2021 and estimated to create US $25.72 million opportunity in 2027 over 2021.

Dual Gastric Balloons

Dual Gastric Balloons segment was valued at US $7.38 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $20.99 million by 2027. Dual Gastric Balloons segment represented US $2.20 million opportunity over 2019-2021 and estimated to create US $11.41 million opportunity in 2027 over 2021.

Triple Gastric Balloons

Triple Gastric Balloons segment was valued at US $5.83 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $16.58 million by 2027. Triple Gastric Balloons segment represented US $1.74 million opportunity over 2019-2021 and estimated to create US $9.01 million opportunity in 2027 over 2021.

Filling Material

Introduction

In 2021, Saline Filled Balloons segment has the highest revenue of US $33.92 million and is expected to grow at CAGR of 12.32% by 2027 Saline Filled Balloons segment has highest cagr growth of 12.32%.

Saline Filled Balloons

Saline Filled Balloons segment was valued at US $26.11 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $74.30 million by 2027. Saline Filled Balloons segment represented US $7.80 million opportunity over 2019-2021 and estimated to create US $40.39 million opportunity in 2027 over 2021.

Gas Filled Balloons

Gas Filled Balloons segment was valued at US $3.72 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $10.59 million by 2027. Gas Filled Balloons segment represented US $1.11 million opportunity over 2019-2021 and estimated to create US $5.75 million opportunity in 2027 over 2021.

Insertion Method

Introduction

In 2021, Endoscopic segment has the highest revenue of US $37.93 million and is expected to grow at CAGR of 12.32% by 2027 Endoscopic segment has highest cagr growth of 12.32%.

Endoscopic

Endoscopic segment was valued at US $29.20 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $83.10 million by 2027. Endoscopic segment represented US $8.73 million opportunity over 2019-2021 and estimated to create US $45.17 million opportunity in 2027 over 2021.

Oral

Oral segment was valued at US $0.63 million in 2019 and is projected to grow at 12.32% CAGR over the forecast period to reach US $1.79 million by 2027. Oral segment represented US $0.19 million opportunity over 2019-2021 and estimated to create US $0.97 million opportunity in 2027 over 2021.